Related Experiment Video

Updated: Apr 26, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

7.7K

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells

Ho-June Lee1, Guanglei Zhuang1, Yi Cao2

  • 1Department of Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.

Cancer Cell
|July 29, 2014
PubMed

Insights

Targeted cancer drugs face resistance from cells activating Stat3. Inhibiting this Stat3 feedback loop, alongside MEK inhibitors, enhances tumor regression and improves drug response in various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Pathway-targeted cancer drugs offer dramatic responses but are limited by drug resistance.
  • Emergence of drug-resistant cells is a major challenge in cancer therapy.
  • Oncogene-addicted cancer cells often develop resistance mechanisms.

Purpose of the Study:

  • To investigate the mechanisms of drug resistance in oncogene-addicted cancer cells.
  • To identify feedback loops contributing to cell survival despite targeted therapy.
  • To explore strategies for overcoming drug resistance and enhancing therapeutic responses.

Main Methods:

  • Analysis of drug-treated cancer cells driven by various activated kinases (EGFR, HER2, ALK, MET) and mutant KRAS.
  • Investigating the role of Signal Transducer and Activator of Transcription 3 (Stat3) activation.
  • Evaluating the effects of MEK inhibition and combined inhibition of MEK, JAK, and FGFR.

Main Results:

  • Drug-treated oncogene-addicted cancer cells activate a positive feedback loop leading to Stat3 activation.
  • This Stat3 activation promotes cell survival and limits drug response across diverse cancer types.
  • MEK inhibition induced autocrine Stat3 activation via FGF receptor and JAK kinases.
  • Combined inhibition of MEK, JAK, and FGFR significantly enhanced tumor regression.

Conclusions:

  • A Stat3 activation feedback loop is a common mechanism of resistance to pathway-targeted cancer drugs.
  • Inhibiting this Stat3 feedback loop can overcome resistance to therapies targeting oncogene addiction.
  • Combination therapy targeting MEK, JAK, and FGFR pathways shows promise for enhanced tumor regression.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

945

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

5.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K